10x Genomics, Inc. TXG NASDAQ

10x Genomics, Inc. (TXG) reported total assets of $1.04B and total liabilities of $245.04M for fiscal year 2025, resulting in total equity of $796.33M.

The company held $523.41M in cash and short-term investments. Total debt stood at $157.74M, with net debt of $-316.23M. The Debt-to-Equity (D/E) ratio was 0.2 (conservative).

Current ratio is 4.46, indicating strong short-term liquidity.

Criteria supported by this page:

• HEALTH (100/100, Pass) — Debt-to-Equity of 0.2, current ratio of 4.46 — balance sheet is strong
• MOAT (55/100) — Total assets $1.04B and equity $796.33M support the company's competitive scale
• VALUE (29/100) — Debt-to-Equity 0.2 contributes to the overall valuation risk assessment

Overall SharesGrow Score: 40/100 with 2/7 criteria passed.

GH

Guardant Health, Inc.

$86.40

+5.10%

TWST

Twist Bioscience Corporation

$57.41

+13.95%

BEAM

Beam Therapeutics Inc.

$30.30

+0.40%

VCYT

Veracyte, Inc.

$34.30

+5.73%

FATE

Fate Therapeutics, Inc.

$1.34

+2.29%

LLY

Eli Lilly and Company

$922.50

-0.76%

JNJ

Johnson & Johnson

$240.10

+0.90%

ABBV

AbbVie Inc.

$210.32

+1.86%